3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 11, 2011, Pages 3390-3394

  Walsh, Shawn P ^a   Severino, Alexandra ^a   Zhou, Changyou ^a   He, Jiafang ^a   Liang, Gui Bai ^a   Tan, Carina P ^a   Cao, Jin ^a   Eiermann, George J ^a   Xu, Ling ^a   Salituro, Gino ^a   Howard, Andrew D ^a   Mills, Sander G ^a   Yang, Lihu ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

3 (4 Aryloxy) propanoic acids; Agonist; Diabetic; GDIS; GPR40

Indexed keywords

BETA SUBSTITUTED 3 (4 ARYLOXYARYL)PROPANOIC ACID; G PROTEIN COUPLED RECEPTOR 40; GLUCOSE; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG SYNTHESIS; GLUCOSE TOLERANCE; HUMAN; IN VIVO STUDY; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; VALIDATION STUDY;

ANIMALS; CYCLIZATION; DISEASE MODELS, ANIMAL; HYPOGLYCEMIC AGENTS; INHIBITORY CONCENTRATION 50; ISLETS OF LANGERHANS; MICE; MOLECULAR STRUCTURE; PROPIONIC ACIDS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 79956141358     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.03.114     Document Type: Article

References (30)

1. M. Prentki, and C.J. Nolan J. Clin. Invest. 116 2006 1802
2. S. Del Guerra, L. Marselli, R. Lupi, U. Boggi, F. Mosca, L. Benzi, S. Del Prato, and K. Marchetti J. Diabetes Complications 19 2005 604
3. C.J. Rhodes Science 307 2005 380
4. M.Y. Donath, and P.A. Halban Diabetologia 47 2004 581
5. G.V. Rayasam, V.K. Tulasi, J.A. Davis, and V.S. Bansal Expert Opin. Ther. Targets 11 2007 661
6. J. Gromada Endocrinology 147 2006 672
7. P. Steneberg, N. Rubins, R. Bartoov-shifman, M.D. Walker, and H. Edlund Cell Metab. 1 2005 245
8. C.P. Briscoe, M. Tadayyon, J.L. Andrews, W.G. Benson, J.K. Chambers, M.M. Eilert, C. Eillis, N.A. Elshourbagy, A.S. Goetz, D.T. Minnick, P.R. Murdock, H.R. Sauls, U. Shabon, L.D. Spinage, J.C. Strum, P.G. Szekeres, K.B. Tan, J.M. Way, D.M. Ignar, S. Wilson, and A.I. Muir J. Biol. Chem. 278 2003 11303
9. K. Kotarsky, N.E. Nilsson, E. Flodgren, C. Owman, and B. Olde Biochem. Biophys. Res. Commun. 301 2003 406
10. F. Song, L. Songfeng, J. Grunnet, J.Z. Xu, P. Wines, J. Proost, Y. Liang, C. Baumann, J. Lenhard, W.V. Murray, K.T. Demarest, and G.-H. Kuo J. Med. Chem. 50 2007 2807
11. S.C. McKeown, D.F. Corbett, A.S. Goetz, T.R. Littleton, E. Bigham, C.P. Briscoe, A.J. Peat, S.P. Watson, and D.M.B. Hickey Bioorg. Med. Chem. Lett. 17 2007 1584
12. D.M. Garrido, D.F. Corbett, K.A. Dwornik, A.S. Goetz, T.R. Littleton, S.C. McKeown, W.Y. Mills, T.L. Smalley, C.P. Briscoe, and A.J. Peat Bioorg. Med. Chem. Lett. 16 2006 1840
13. P.S. Humphries, J.W. Benbow, P.D. Bonin, D. Boyer, S.D. Doran, R.K. Frisbie, D.W. Pietrowski, G. Balan, D.M. Bechle, E.L. Conn, K.J. Dirico, R.M. Oliver, W.C. Soeller, J.A. Southers, and X. Yang Bioorg. Med. Chem. Lett. 19 2009 2400
14. N.J. Smith, L.A. Stoddard, N.M. Devine, L. Jenkins, and G. Milligan J. Biol. Chem. 26 2009 17527
15. N. Negoro, S. Sasaki, S. Mikami, M. Ito, M. Suzuki, Y. Tsujihata, R. Ito, A. Harada, K. Takeuchi, N. Suzuki, J. Miyazaki, T. Santou, T. Odani, N. Kanzaki, N. Funami, T. Tanaka, A. Kogame, S. Matsunaga, T. Yasuma, and Y. Momose Med. Chem. Lett. 1 2010 290
16. E. Christiansen, M.E. Due-Hansen, C. Urban, M. Merten, M. Pfleiderer, K.K. Karlsen, S.S. Rasmussen, M. Steensgaard, A. Hamacher, J. Schmidt, C. Drewke, R.K. Petersen, K. Kristiansen, S. Ullrich, E. Kostenis, M.U. Kassack, and T. Ulven Med. Chem. Lett. 1 2010 345
17. Y. Itoh, Y. Kawamata, M. Harada, M. Kobayashi, Fujii, S. Fukusumi, K. Ogi, M. Hosoya, Y. Tanaka, H. Uejima, H. Tanaka, M. Maruyama, R. Satoh, S. Okubo, H. Kizawa, H. Komatsu, F. Matsumura, Y. Noguchi, T. Shinohara, S. Hinuma, Y. Fujisawa, and M. Fujino Nature 422 2003 173
18. C. Zhou, C. Tang, E. Chang, M. Ge, S. Lin, E. Cline, C.P. Tan, Y. Feng, Y.-P. Zhou, G.J. Eiermann, A. Petrov, G. Salitoro, P. Meinke, R. Mosley, T.E. Akiyama, M. Einstein, S. Kumar, J. Berger, A.D. Howard, N. Thornberry, S.G. Mills, and L. Yang Bioorg. Med. Chem. Lett. 20 2010 1298
19. C.P. Tan, Y. Feng, Y.-P. Zhou, G.J. Eiermann, A. Petrov, C. Zhou, S. Lin, G. Salituro, P. Meinke, R. Mosley, T.E. Akiyama, M. Einstein, S. Kumar, J. Berger, S.G. Mills, N.A. Thornberry, L. Yang, and A.D. Howard Diabetes 57 2008 2211
20. For other examples of β-substituted propionic acid GPR40 agonists see:
21. Ackerman, M.; Houze, J.; Lin, D. C. H.; Liu, J.; Liu, J.; Luo, J.; Ma, Z.; Medina, J. C.; Qiu, W.; Reagan, J. D.; Sharma, R.; Schmitt, M. J.; Shuttleworth, S. J.; Sun, Y.; Wang, Y.; Zhang, J.; Zhu, L. US20070142384A1, 2007.
22. Ackerman, M.; Brown, S.; Houze, J.; Liu, J.; Liu, J.; Ma, Z.; Medina, J. C.; Qiu, W.; Schmitt, M. J.; Sharma, R.; Wang, Y.; Zhu, L. US20070066647A1, 2007.
23. Ackerman, M.; Houze, J.; Lin, D. C. H.; Liu, J.; Luo, J.; Medina, J. C.; Qiu, W.; Reagan, J. D.; Sharma, R.; Schmitt, M. J.; Shuttleworth, S. J.; Sun, Y.; Wang, Y.; Zhang, J.; Zhu, L. US20060004012A1, 2006.
24. Fluorometric imaging plate reader (FLIPR) based intracellular calcium assay is described fully in Ref. 7b. All reported values are means of ≥3 experiments, with standard deviations <75% of the average.
25. D.A. Evans, K.A. Woerpel, M.M. Hinman, and M.M. Faul J. Am. Chem. Soc. 113 1991 728
26. 1H NMR spectra and are in agreement with previously biological activity of previously reported GPR40 agonists (Ref. 5b).
27. SPA binding assay was carried out using receptor isolated from CHO cells overexpressing human GPR40. All reported values are means of ≥3 experiments, with standard deviations <75% of the average.
28. 4, THF, 0 °C (72%).
29. IP3 assay protocol is described in Ref. 7b.
30. For a full account of the experimental protocol used in the IPGTT assay see Ref. 7b.